Table 2.
Covariate | HR | 95% CI | p-value |
---|---|---|---|
Age | 1.63 | 1.08 – 2.45 | 0.0188 |
Gender Male | 1.47 | 0.80 – 2.69 | 0.2109 |
Stage | 1.3 | 0.26 – 6.45 | 0.0001 |
II | 3.7 | 1.03 – 13.26 | |
III | 9.49 | 3.18 – 28.36 | |
IV | |||
LDH | 1.32 | 1.10 – 1.60 | 0.0027 |
Treatment Surgery | 0.14 | 0.06 - .33 | <0.0001 |
Location | 1.05 | 0.46 – 2.40 | 0.1934 |
HN | 0.45 | 0.16 – 1.24 | |
LE | 0.49 | 0.21 – 1.12 | |
UE | l.28 | 0.42 – 3.84 | |
Other | |||
Serum APRIL/TNFSF13Hi | 0.64 | 0.43 – 0.95 | 0.0285 |
Serum CCL19Hi | 1.2 | 0.88 – 1.64 | 0.2453 |
Serum CXCL10Hi | 1.213 | 0.91 – 1.42 | 0.2616 |
Serum CXCL13Hi | 0.81 | 0.59 – 1.10 | 0.1785 |
LDH, Lactate dehydrogenase; HN, Hilar nodes; LE, Lower extremity; UE, Upper extremity.